Elsevier,
The Lancet Global Health, Volume 10, June 2022
Background: An alarming number of public health-care facilities in low-income and middle-income countries lack basic water, sanitation, hygiene (WASH), and waste management services. This study estimates the costs of achieving full coverage of basic WASH and waste services in existing public health facilities in the 46 UN designated least-developed countries (LDCs). Methods: In this modelling study, in-need facilities were quantified by combining published counts of public facilities with estimated basic WASH and waste service coverage.
Elsevier,
Trees, Forests and People, Volume 8, June 2022
Sustainable wood-based design solutions necessarily presuppose economically, socially, and environmentally reliable sources of wood use for any future designs. However, increasingly unsustainable effects from climate extremity are now prompting the search for alternative forms of use that avoid or forestall those effects.
Elsevier,
The Lancet Regional Health - Americas, Volume 10, June 2022
A Health Policy paper on the health impacts of banned pesticides in the Yaqui population in Mexico, in the context of SDGs 3, 10, and 12, highlighting recommendations for system-level solutions and policy change to current US, UN, and global laws.
Elsevier, Future Foods, Volume 5, June 2022
Plant-based meat substitutes are products used to replace meat in the human diet. These products have developed from traditional whole-grain meat substitutes to products based on an advanced technology called 2nd generation meat substitutes. Increased market visibility of 2nd generation products raised questions about the products´ healthiness once they are classified by NOVA as ultra-processed, are allegedly high in salt and saturated fat, and might not be nutritionally equivalent to meat.
Elsevier,
eBioMedicine, Volume 80, June 2022
This Article supports SDG 3 by assessing the safety, tolerability, pharmacokinetics, and anti-fibrotic effects of PRI-724 in patients with cirrhosis due to hepatitis B virus and hepatitis B virus, for which there is currently no anti-fibrotic drug therapy available; PRI-724 was well tolerated but further evaluation of its anti-fibrotic effects is warranted.
